ArticleScientific reports2026
FAM111B may promote the progression of lung squamous cell carcinoma through PI3K signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lung squamous cell carcinoma (LUSC) is a subtype of non-small cell lung cancer (NSCLC). Compared to lung adenocarcinoma (LUAD), LUSC is characterized by a greater propensity for recurrence and metastasis, poorer prognosis, and shorter survival. Therefore, further research into the pathogenesis of LUSC and the identification of new therapeutic targets are essential to advance clinical treatment options for this aggressive cancer. FAM111B, a serine protease and cancer-associated nuclear protein, has been implicated in various cancers. Previous studies have shown that FAM111B is closely associated with the progression of LUAD. However, our pan-cancer analysis suggests that FAM111B is highly expressed in LUSC and plays an oncogenic role, which is consistent with its higher expression in LUSC compared to LUAD in clinical samples. To investigate the functional role of FAM111B in LUSC, we developed both in vitro and in vivo knockdown models. Our results demonstrate that knocking down FAM111B significantly inhibits the proliferation, migration, and invasion of LUSC cells. Additionally, FAM111B knockdown induces cell cycle arrest in the S phase, further underscoring its role in LUSC progression. Mechanistically, FAM111B promotes LUSC migration and invasion by facilitating epithelial-mesenchymal transition (EMT). Moreover, the proliferation and cell cycle processes in LUSC may be regulated through the PI3K signaling pathway. In conclusion, our study elucidates the clinical relevance and molecular mechanisms of FAM111B in LUSC, highlighting its potential as a novel therapeutic target for this challenging cancer subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.